1 Min Read
Oct 11 (Reuters) - NanoCarrier Co Ltd :
* Says it confirmed safety profile and efficacy of NC-6004 in the Phase Ib clinical study conducted in the U.S.
Source text in Japanese:goo.gl/XsXi3w
Further company coverage: (Beijing Headline News)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.